Eidetics’ Oncology Practice Area

Providing sophisticated oncology market research support has long been a hallmark of Eidetics’ strategic clinical capabilities.  Now, our Oncology Specialty Practice expands the scope of our cutting-edge research and rich clinical knowledge, and allows us to further tailor methodologies to the unique needs of the oncology marketplace.

Why Oncology?

Oncology is different.  Treatment algorithms for high-stakes categories are never as securely evidence-based as one might wish; clinicians often have to be creative in the face of uncertainty.

Oncology is important.  Cancer is projected to be the leading cause of death in the US by 2010.  The pharmaceutical industry feels pressure to be more productive because of the high degree of need, the explosion of scientific developments in these areas, and the relative price insensitivity of the market.  Our clients have made oncology drug development a strategic investment priority; we have made supporting them a strategic research priority.

Translating Research into Strategy

Eidetics’ researchers have a passion for understanding the clinical and market dynamics of cancer treatment and supportive care.  As a team, Oncology Practice consultants dedicate the majority of their time to studying — and interpreting — the oncology marketplace. We offer:

• A sound understanding of the marketplace, recognizing that “science” is often NOT the primary driver of market behavior
• Proven techniques for eliciting clinically complex and often personally sensitive information from MDs, nurses, and patients
• Sophisticated quantitative modeling adapted to the unique needs of the oncology market

Specific Experience

As a company, we have completed hundreds of major projects in the oncology, hematology, and supportive care markets — the majority of those in the past five years.

Eidetics’ broad base of experience can help ensure your oncology research stays relevant in today’s changing marketplace.  

Contact us at oncology@eidetics.com for more information.